METHYLOMIC Matters

In the first episode of METHYLOMIC matters we will speak with dr. Anje te Velde and Professor Wouter de Jonge, diving into the concept of DNA methylation changes in IBD and their potential to be used as biomarkers of therapy response in IBD. What is epigenetics and how does it work? Why is DNA methylation interesting in complex immune mediated diseases and what is the history behind the EPIC-CD and METHYLOMIC projects? All this and more in the first episode of METHYLOMIC matters!

In the second episode of METHYLOMIC matters we have the privilege of conversing with Professor Geert D’Haens and Dr. Andrew Li Yim as we delve into the pre-METHYLOMIC era and discover the science behind the OMICROHN trial: the EPIC-CD study. How did we design this biomarker discovery study and what are key important methodological steps? What were the main results and how do we envision the future? All this and more in the second episode of METHYLOMIC matters!

In the third episode of METHYLOMIC matters we delve into the intricate machine learning methodology behind the successful prediction models developed by HORAIZON’s founder and CEO, dr. Evgeni Levin. We explore essential elements of the methodology, comparing linear and non-linear models, emphasizing the significance of multivariate models, and addressing strategies for mitigating overfitting. Furthermore, we delve into the prospective clinical applications of these models and their ultimate integration into clinical practice. All this and more in the third episode of METHYLOMIC matters!

In the fourth episode of METHYLOMIC matters our attention centers on a crucial element of METHYLOMIC: the development of an easy-to-use diagnostic test intended for clinical validation, with the ultimate aim of global adoption in medical centers. With Dr. Peter Henneman and Dr. Jules Petit we discuss the importance of a rapid assay and compare its pros and cons opposed to the current EPIC array methodology. All this and more in the fourth episode of METHYLOMIC matters!